Emily Menendez

GI Oncology Now

A lack of knowledge exists in understanding the influence of inflammatory markers on the prognosis of high-risk patients with gastrointestinal stromal tumors (GISTs). To determine the link between certain factors and the prognosis of these patients, <a href="https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-025-03710-8" target="_blank" rel="noopener">a recent multicenter analysis</a> focused on recurrence-free survival (RFS) and overall survival (OS) as prognostic indicators.
Data were collected from 145 high-risk patients with GIST from 17 different medical centers from January 2013 to December 2019. Variables were analyzed with single-factor analysis and survival curves, while independent prognostic factors were measured using a Cox regression model.
A univariate analysis found links between RFS and age, preoperative neutrophil-to-lymphocyte ratio (NLR), preoperative platelet-to-lymphocyte ratio (PLR), preoperative systemic immune-inflammatory index (SII), preoperative prognostic nutritional index (PNI), mitotic index, and whether imatinib (IM) was taken regularly in high-risk patients with GIST (P&lt;0.05). Each factor other than age was also significantly correlated with OS (P&lt;0.05).
Cox regression analysis identified age, preoperative PNI, mitotic index, and postoperative IM adjuvant therapy as independent predictors of RFS (P&lt;0.05). Additionally, preoperative PNI and postoperative IM adjuvant therapy were significantly associated with OS (P&lt;0.05). Age negatively correlated with RFS, while early routine IM treatment post-surgery significantly lowered the risk for recurrence and mortality. A higher mitotic index was linked to poorer RFS, whereas an elevated preoperative PNI indicated a more favorable prognosis.
Factors including young age, low preoperative PNI, high mitotic index, and lack of IM treatment were linked to an unfavorable prognosis in high-risk patients with GIST. PNI can also be an additional prognostic factor and can be a valuable addition to standard clinical practice for this patient population.

A lack of knowledge exists in understanding the influence of inflammatory markers on the prognosis of high-risk patients with gastrointestinal stromal tumors (GISTs). To determine the link between certain factors and the prognosis of these patients, <a href="https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-025-03710-8" target="_blank" rel="noopener">a recent multicenter analysis</a> focused on recurrence-free survival (RFS) and overall survival (OS) as prognostic indicators.Data were collected from 145 high-risk patients with GIST from 17 different medical centers from January 2013 to December 2019. Variables were analyzed with single-factor analysis and survival curves, while independent prognostic factors were measured using a Cox regression model.A univariate analysis found links between RFS and age, preoperative neutrophil-to-lymphocyte ratio (NLR), preoperative platelet-to-lymphocyte ratio (PLR), preoperative systemic immune-inflammatory index (SII), preoperative prognostic nutritional index (PNI), mitotic index, and whether imatinib (IM) was taken regularly in high-risk patients with GIST (P&lt;0.05). Each factor other than age was also significantly correlated with OS (P&lt;0.05).Cox regression analysis identified age, preoperative PNI, mitotic index, and postoperative IM adjuvant therapy as independent predictors of RFS (P&lt;0.05). Additionally, preoperative PNI and postoperative IM adjuvant therapy were significantly associated with OS (P&lt;0.05). Age negatively correlated with RFS, while early routine IM treatment post-surgery significantly lowered the risk for recurrence and mortality. A higher mitotic index was linked to poorer RFS, whereas an elevated preoperative PNI indicated a more favorable prognosis.Factors including young age, low preoperative PNI, high mitotic index, and lack of IM treatment were linked to an unfavorable prognosis in high-risk patients with GIST. PNI can also be an additional prognostic factor and can be a valuable addition to standard clinical practice for this patient population.

Olatunji B. Alese, MD

Precision, Access, and Equity: Dr. Olatunji Alese’s Vision for GI Oncology Care

Bile Duct Cancer

FLOT Plus Perioperative Chemotherapy Improves Esophageal Cancer Survival Rates Compared With CROSS

Esophageal Cancer

Kimberly Perez, MD

Targeting VEGF Pathways in Advanced NETs: Ramucirumab Plus Somatostatin Analog Therapy

GEP-NETs

Latest News

Inflammatory Markers and Prognosis in High-Risk GIST

GIST

Factors including young age, low preoperative PNI, high mitotic index, and lack of IM treatment were linked to an unfavorable prognosis in high-risk patients with GIST.